Preclinical validation and phase I trial of 4-hydroxysalicylanilide, targeting ribonucleotide reductase mediated dNTP synthesis in multiple myeloma.
Xie Y, Wang Y, Xu Z, Lu Y, Song D, Gao L, Yu D, Li B, Chen G, Zhang H, Feng Q, Zhang Y, Hu K, Huang C, Peng Y, Wu X, Mao Z, Shao J, Zhu W, Shi J.
Xie Y, et al. Among authors: xu z.
J Biomed Sci. 2022 May 12;29(1):32. doi: 10.1186/s12929-022-00813-2.
J Biomed Sci. 2022.
PMID: 35546402
Free PMC article.
Clinical Trial.